Prevention and treatment of motor fluctuations

Parkinsonism and Related Disorders

Volumn 9, Issue SUPPL. 2, 2003, Pages 73-81

  Stocchi, Fabrizio ^a  

^a National Institute of Neuroscience   (Italy)

Author keywords

Advanced Parkinson's disease; COMT inhibitors; Dopamine agonists; Dyskinesias; Levodopa

Indexed keywords

ANTIPARKINSON AGENT; APOMORPHINE; BENSERAZIDE PLUS LEVODOPA; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; DOMPERIDONE; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; ETILEVODOPA; LEVODOPA; LEVODOPA METHYL ESTER; LISURIDE; PERGOLIDE; PIRIBEDIL; PRAMIPEXOLE; ROPINIROLE; TOLCAPONE; UNCLASSIFIED DRUG;

ADD ON THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED DRUG RELEASE; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DOSE CALCULATION; DRUG ABSORPTION; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DYSKINESIA; HALLUCINATION; HUMAN; INFUSION PUMP; LIVER CELL DAMAGE; LONG TERM CARE; MOTOR DYSFUNCTION; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROPHYLAXIS; RISK MANAGEMENT; SOMNOLENCE; STOMACH EMPTYING; SYMPTOM; VOMITING;

EID: 0041659345     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(03)00021-X     Document Type: Conference Paper

References (94)

1. Olanow C.W., Watts R.L., Koller W.C. An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. Neurology. 56:(Suppl. 5):2001;S1-S86.
2. Agid Y., Olanow C., Mizuno Y. Levodopa: why the controversy? Lancet. 360:(9332):2002;575.
3. Miyasaki J.M., Martin W., Suchowersky O., Weiner W.J., Lang A.E. Practice parameter: initiation of treatment for PD: an evidence-based review. Report of the quality standards subcommittee of the American academy of neurology. Neurology. 58:2002;11-17.
4. Rascol O., Goetz C., Koller W., Poewe W., Sampaio C. Treatment interventions for Parkinson's disease: an evidence-based assessment. Lancet. 359:2002;1589-1598.
5. Korczyn A.D., Nussbaum M. Emerging therapies in the pharmacological treatment of Parkinson's disease. Drugs. 62:(5):2002;775-786.
6. Marsden C.D., Parkes J.D. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet. 1:1977;345-349.
7. Marsden C.D. Parkinson's disease. J Neurol Neurosurg Psychiatry. 57:1994;672-681.
8. Luquin M.R., Scipioni O., Vaamonde J., Gershanik O., Obeso J.A. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Mov Disord. 7:1992;117-124.
9. Marconi R., Lefebvre-Caparros D., Bonnet A.M., Vidailhet M., Dubois B., Agid Y. Levodopa-induced dyskinesias in Parkinson's disease: phenomenology and pathophysiology. Mov Disord. 9:1994;2-12.
10. Melamed E., Bitton V., Zelig O. Episodic unresponsiveness to single doses of L-Dopa in parkinsonian fluctuators. Neurology. 36:1986;100-103.
11. Quinn N., Critchley P., Marsden C.D. Young onset Parkinson's disease. Mov Disord. 2:1987;73-91.
12. Marsden C.D., Parkes J.D. On-off effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet. 1:1976;292-296.
13. Fabbrini G., Juncos J., Mouradian M.M., Serrati C., Chase T.N. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Ann Neurol. 21:1987;370-376.
14. Fabbrini G., Mouradian M.M., Juncos J., et al. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms. Part I. Ann Neurol. 24:1988;366-371.
15. Mouradian M.M., Juncos J.L., Fabbrini G., Schlegel J., Bartko J.J., Chase T.N. Wearing-off fluctuations in Parkinson's disease: central pathophysiology mechanisms. Part II. Ann Neurol. 24:1988;372-378.
16. Bravi D., Mouradian M.M., Roberts J.W., Davis T.L., Sohn Y.H., Chase T.N. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Ann Neurol. 36:1994;27-31.
17. Rodriguez M., Lera G., Vaamonde J., Luquin M.R., Obeso J.A. Motor response to apomorphine and levodopa in asymmetric Parkinson's disease. J Neurol Neurosurg Psychiatry. 57:1994;562-566.
18. Mouradian M.M., Juncos J.L., Fabbrini G., Chase T.N. Motor fluctuations in Parkinson's disease. Ann Neurol. 25:1989;633-634.
19. Nutt J.G. Levodopa-induced dyskinesia: review, observations and speculations. Neurology. 40:1990;340-345.
20. Muenter M.D., Tyce G.M. L-dopa therapy of Parkinson's discese in plasma L-dopa concentration, therapeutic response, and side effects. Mayo Clin Proc. 46:1971;231-239.
21. Kaye J.A., Feldman R.G. The role of L-dopa holiday in the long term management of Parkinson's disease. Clin Neuropharmacol. 9:1986;1-13.
22. Barbato L., Stocchi F., Monge A., et al. The long-duration action of levodopa may be due to a post-synaptic effect. Clin Neuropbarmacol. 20:1997;394-401.
23. Stocchi F., Vacca L., Berardelli A., De Pandis M.F., Ruggieri S. The long-lasting effect and the postsynaptic compartment: a study using a dopamine agonist with a short half-life. Mov Disord. 16:2001;301-305.
24. Stocchi F., Vacca L., Berardelli A., Barbato L., Valente M., Ruggieri S. Dopamine agonists and the long duration effect (abs). Parkinsonism Related Disord. 7:(Suppl.):2001;S70.
25. Obeso J.A., Rodriguez-Oroz M.C., Rodriguez M., Lanciego J.L., Artieda J., Gonzalez N., Olanow C.W. Pathophysiology of the basal ganglia in PD. Trends Neurosci. 23:2000;8-19.
26. Obeso J.A., Rodriguez-Oroz M.C., Rodriguez M., DeLong M.R., Olanow C.W. Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with current models of the basal ganglia. Ann Neurol. 47:2000;22-34.
27. Olanow C.W., Schapira A.H.V., Rascol O. Continuous dopaminergic stimulation in the early treatment of PD. Trends Neurosci. 23:2000;117-126.
28. Abercrombie E.D., Bonatz A.E., Zigmond M.J. Effects of L-DOPA on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res. 525:1990;36-44.
29. Tedroff J., Pedersen M., Aquilonius S., Hartvig P., Jacobsson G., Langstrom B. Levodopainduced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET. Neurology. 46:1996;1430-1436.
30. Calon F., Grondin R., Morissette M., et al. Molecular basis of levodopa-induced dyskinesias. Ann Neurol. 47:1998;70-78.
31. Filion M., Tremblay L., Bedard P.J. Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism. Brain Res. 547:1991;152-161.
32. Chase T.N., Baronti F., Fabbrini G., et al. Rationale for continous dopamimetic therapy of Parkinson's disease. Neurology. 39:1989;7-10.
33. Pearce R.K., Banerji T., Jenner P., Marsden C.D. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov Disord. 13:1998;234-241.
34. Blanchet P.J., Calon F., Martel J.C., et al. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys. J Pharmacol Exp Ther. 272:1995;854-859.
35. Morissette M., Goulet M., Soghomonian J.J., et al. Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy. Mol Brain Res. 49:1997;55-62.
36. Rascol O., Brooks D.J., Korczyn A.D., et al. A five year study of the incidence of dyskinesia in patients with early parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med. 342:2000;1484-1491.
37. Pramipexole vs levodopa as initial treatment for Parkinson's disease. JAMA. 284:2000;231-238.
38. Rinne U.K., Bracco F., Chouza C., et al. Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 collaborative Study Group. Neurology. 48:1997;363-368.
39. Barone P., Bravi D., Bermejo-Pareja F., Marconi R., Kulisevsky J., Malagu S., Weiser R., Rost N. Pergolide monotherapy in the treatment of early PD: a randomized, controlled study. Pergolide monotherapy study group. Neurology. 53:1999;573-579.
40. Fariello R.G. Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease. Drugs. 55:(Suppl. 1):1998;10-16.
41. Sit S.Y. Dopamine agonists in the treatment of Parkinson s disease past, present and future. Curr Pharm Des. 6:(12):2000;1211-1248.
42. Baas H.K., Schueler P. Efficacy of cabergoline in long-term use: results of three observational studies in 1,500 patients with Parkinson's disease. Eur Neurol. 46:(Suppl. 1):2001;18-23.
43. Baruzzi A., Contin M., Riva R., et al. Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in parkinsonian patients. Clin Neuropharmacol. 10:1987;527-537.
44. Edwards L.L., Quingley E.M.M., Pfeiffer R.F. Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology. Neurology. 42:1992;726-732.
45. Valenzuela J.E. Dopamine as a possible neurotransmitter in gastric relaxation. Gastroenterology. 71:1976;1019-1022.
46. Leon A.S., Speigel H. The effect of antacid administration on the absorption and metabolism of levodopa. J Clin Pharmacol. 12:1972;263-267.
47. Kelly K.A. Motility of the stomach and gastroduodenal junction. Johnson L.R. Physiology of the gastrointestinal tract. 1981;394-410 Raven Press, New York.
48. Sage J.I., Trooskin S., Sonsalla P.K., Heikkila R.E., Duvoisin R.C. Longterm duodenal infusion of levodopa for motor fluctuations in parkinsonism. Ann Neurol. 24:1998;87-89.
49. Kurlan R., Rubin A.J., Miller C., et al. Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations. Ann Neurol. 20:1986;262-265.
50. Syed N., Murphy J., Zimmerman T., Mark M.H., Sage J.I. Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease. Mov Disord. 13:1998;336-338.
51. Nutt J.G., Woodward W.R., Hammerstad J.P., et al. The on-off phenomenon in Parkinson's disease: relation to levodopa absorption and transport. N Engl J Med. 310:1984;483-488.
52. 19F)-fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Ann Neurol. 20:1986;258-262.
53. Kurth M.C., Tetrud J.W., Tanner C.M., Irwin I., Stebbins G.T., Goetz C.G., Langston J.W. Doubleblind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with on-off fluctuations. Neurology. 43:1993;1698-1703.
54. Stocchi F., Ruggieri S., Monge A., et al. Clinical efficacy of single morning doses of different levodopa formulations. Clin Neuropharmacol. 17:(Suppl. 3):1994;S16-S20.
55. Stocchi F., Barbato L., Bramante L., Nordera G., Vacca L., Ruggieri S. Fluctuating parkinsonism: a pilot study of single afternoon dose of levodopa methyl ester. J Neurol. 243:(5):1996;377-380.
56. Steiger M.J., Stocchi F., Bramante L., Ruggieri S., Quinn N.P. The clinical efficacy of single morning doses of levodopa methyl ester: dispersible Madopar and Sinemet plus in Parkinson disease. Clin Neuropharmacol. 15:(6):1992;501-504.
57. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol. 42:1997;747-755.
58. Poewe W., Deuschl G., Gordin A., Celomen Study Group. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a six-months randomized placebo-controlled double-blind study in Germany and Austria. Acta Neurol Scand. 105:(4):2002;245-255.
59. Larsen J.P., Siden A., Worm-Peterson J., et al. Long-term efficacy and safety of entacapone in Parkinsonian patients with motor fluctuations: a Nordic open study of 3 years duration (abs). Parkinsonism Related Disord. 7:(Suppl.):2001;S61.
60. Sagar H., Brooks D., UK-Irish Entacapone Study Group. The UK-Irish double-blind study of entacapone in Parkinson's disease. Mov Disord. 15:(Suppl. 3):2000;135.
61. Durif F., Devaux I., Pere J.J., Delumeau J.C., Bourdeix I. Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study. Eur Neurol. 45:2001;111-118.
62. Adler C.H., Singer C., O'Brien C., Hauser R.A., Lew M.F., Marek K.L., Dorflinger E., Pedder S., Deptula D., Yoo K. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III. Arch Neurol. 55:1998;1089-1095.
63. Troconiz I.F., Naukkarinen T.H., Ruottinen H.M., Rinne U.K., Gordin A., Karlsson M.O. Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone. Clin Pharmacol Ther. 64:1998;106-116.
64. Baas H., Zehrden F., Selzer R., Kohnen R., Loetsch J., Harder S. Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease. Clin Pharmacokinet. 40:2001;383-393.
65. Nutt J.G., Woodward W.R., Beckner R.M., Stone C.K., Berggren K., Carter J.H., Gancher S.T., Hammerstad J.P., Gordin A. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology. 44:1994;913-919.
66. Kaakkola S., Teravainen H., Ahtila S., Rita H., Gordin A. Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology. 44:1994;77-80.
67. Olanow C.W., Tasmar Advisory Panel. Tolacapone and hepatotoxic effects. Arch Neurol. 57:2000;263-267.
68. Assal F., Spahr L., Hadengue A., Rubbia-Brandt L., Burkhard P.R., Rubbici-Brandt L. Tolcapone and fulminant hepatitis. Lancet. 352:1998;958.
69. Blum M.W., Siegel A.M., Meier R., Hess K. Neuroleptic malignant-like syndrome and acute hepatitis during tolcapone and clozapine medication. Eur Neurol. 46:2001;158-160.
70. Olanow C.W., Obeso J.A. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for early use of COMT inhibitors. Neurology. 55:(Suppl. 4):2000;S72-S77.
71. Langtry H.D., Clissold S.P. Pergolide: a review of its pharmacological properties and therapeutic potential in Parkinson's disease. Drugs. 39:1990;491-506.
72. Rabey J.M., Streifler M., Treves T., Korczyn A.D. A long-term comparative study of lisuride and levodopa in Parkinson's disease. Calne J.M., Comi G., Crippa D., et al. Parkinsonism and aging. 1989;261-267 Raven Press, New York.
73. Hutton J.T., Morris J.L., Brewer M.A. Controlled study of the antiparkinsonian activity and tolerability of cabergoline. Neurology. 43:1993;613-616.
74. Rabey J.M., Nissipeanu P., Inzelberg R., Korczyn A.D. Beneficial effect of cabergoline, new longlasting D-2 agonist in the treatment of Parkinson's disease. Clin Neuropharmacol. 17:1994;286-293.
75. Rinne U.K., Bracco F., Chousa C., et al. Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. Neurology. 48:1997;363-368.
76. Korczyn A.D., Brooks D.J., Brunt E.R., et al. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group. Mov Disord. 13:1998;46-51.
77. Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment in the treatment of early Parkinson's disease. International Pramipexole-Bromocriptine Study Group. Neurology. 49:1997;1060-1065.
78. Mizuno Y., Kondo T., Narabayashi H. Pergolide in the treatment of Parkinson's disease. Neurology. 45:1995;S13-S21.
79. Pezzoli G., Martignoni E., Pacchetti C., et al. Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study. Mov Disord. 9:1994;431-436.
80. Corsini G.U., Del Zompo M., Gessa G.L., Mangoni A. Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease. Lancet. 1:(8123):1979;954-956.
81. Frankel J.P., Lees A.J., Kempster P.A., Stern G.M. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry. 53:1990;96-101.
82. Hughes A., Bishop S., Kleedorfer B., et al. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord. 8:1993;165-170.
83. Attanasio A., Capria C., Leggiardro G., et al. Transient cardiac arrest during continuous intravenous infusion of apomorphine. Lancet. 336:(8726):1990;1321.
84. Olanow C.W., Obeso J.A. Preventing levodopa-induced dyskinesia. Ann Neurol. 47:2000;167-178.
85. Hadj Tahar A., Gregoire L., Bangassoro E., Bedard P.J. Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys. Clin Neuropharmacol. 23:2000;195-202.
86. Pearce R.K., Banerji T., Jenner P., Marsden C.D. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov Disord. 13:1998;234-241.
87. Stocchi F., Ruggieri S., Vacca L., Olanow C.W. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. Brain. 125:2002;2058-2066.
88. Vaamonde J., Luquin M.R., Obeso J.A. Subcutaneous lisuride infusion in Parkinson's disease: response to chronic administration in 34 patients. Brain. 114:1991;601-614.
89. Stocchi F., Bramante L., Monge A., Viselli F., Baronti F., Stefano E., Ruggieri S. Apomorphine and lisuride infusion: a comparative study. Adv Neurol. 60:1993;653-655.
90. Colzi A., Turner K., Lees A.J. Continuous subcutaneous waking day apomorphine in the long-term treatment of levodopa induced dyskinesia in Parkinson's disease. J Neurol Neurosurg Psychiatry. 64:1998;573-576.
91. Stibe C.M.N., Lees A.J., Kempster P.A., Stern G.M. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet. 1:(8582):1988;403-406.
92. Pietz K., Hagell P., Odin P. Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up. J Neurol Neurosurg Psychiatry. 65:1998;709-716.
93. Nilsson D., Hannsson L., Johansson K., Nystrom C., Paalzow L.K., Aquilonius S. Longterm intraduodenal infusion of a water based levodopacarbidopa dispersion in very advanced Parkinson's disease. Acta Neurol Scand. 97:1998;175-183.
94. Stocchi F., Farina C., Nordera G.P., Ruggieri S. Implantable venous access system for apomorphine infusion in complicated Parkinson's disease. Mov Disord. 14:1999;358.